JPRN-UMIN000002461已完成未知
Effect of pioglitazone in combination with glimepiride therapy on various parameters of insulin resistance including lipoprotein subclass levels in patients with type 2 diabetes - Effect of pioglitazone on insulin resistance parameters
Yamashiro Public Hospital0 个研究点目标入组 50 人开始时间: 2009年9月10日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •(i) a serum creatinine concentration ≥106 µmol/l; (ii) chronic liver disease or a clinical history and/or signs of cardiovascular, cerebrovascular or peripheral arterial disease; (iii) heavy smoking or drinking; and (iv) use of thiazolidinediones, biguanides and/or insulin in the 3 months preceding the study.
研究者
相似试验
进行中(未招募)
不适用
Effects of Pioglitazone in Combination with Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients with Type 2 Diabetes mellitusEUCTR2006-002271-41-DETakeda Pharma GmbH
招募中
不适用
The effect of pioglitazone on reducing methamphetamine dependence.Methamphetamine dependent patients.IRCT20190427043389N1Zanjan University of Medical Sciences100
已完成
3 期
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.Diabetes MellitusNCT00770952Takeda91
招募中
不适用
The effect of pioglitazone on reducing opioid and heroin dependence.IRCT20190427043389N2Zanjan University of Medical Sciences100
进行中(未招募)
不适用
Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and an activated inflammationA randomized double-blinded phase II studyon-diabetic hypertensive patients with a hsCRP value > 1.0 mg/L < 10.0 mg/L and pretreated with ACE inhibitors for at least 12 weeks are eligible for study participation.MedDRA version: 8.1Level: LLTClassification code 10003601Term: AtherosclerosisEUCTR2006-004028-35-DETakeda Pharma GmbH
